Assay-related differences in SuPAR levels: implications for measurement and data interpretation.
作者信息
Vasbinder Alexi, Raffield Laura Marie, Gao Yan, Engstrom Gunnar, Quyyumi Arshed Ali, Reiner Alexander Paul, Reiser Jochen, Hayek Salim Salim
机构信息
Division of Cardiology, Department of Medicine, University of Michigan Frankel Cardiovascular Center, 1500 E Medical Center Dr, CVC #2709, Ann Arbor, MI, 48109, USA.
Department of Genetics, University of North Carolina, Chapel Hill, NC, USA.
出版信息
J Nephrol. 2023 Jan;36(1):157-159. doi: 10.1007/s40620-022-01344-7. Epub 2022 May 14.
Abstract
摘要
相似文献
1
Assay-related differences in SuPAR levels: implications for measurement and data interpretation.可溶性尿激酶型纤溶酶原激活物受体（SuPAR）水平与检测方法相关的差异：对测量和数据解读的影响
J Nephrol. 2023 Jan;36(1):157-159. doi: 10.1007/s40620-022-01344-7. Epub 2022 May 14.
2
Effects of acute exercise and allopurinol administration on soluble urokinase plasminogen activator receptor (suPAR).急性运动和给予别嘌呤醇对可溶性尿激酶型纤溶酶原激活物受体（suPAR）的影响。
Clin Lab. 2013;59(1-2):207-10. doi: 10.7754/clin.lab.2012.120728.
3
Clinical and prognostic usefulness of soluble urokinase plasminogen activator receptor in hemodialysis patients.可溶性尿激酶型纤溶酶原激活物受体在血液透析患者中的临床及预后价值
Int Urol Nephrol. 2018 Feb;50(2):339-345. doi: 10.1007/s11255-017-1778-5. Epub 2018 Jan 8.
4
Elevated preoperative suPAR is a strong and independent risk marker for postoperative complications in patients undergoing major noncardiac surgery (SPARSE).术前 suPAR 升高是行大非心脏手术患者术后并发症的一个强而独立的风险标志物（SPARSE）。
Surgery. 2022 Jun;171(6):1619-1625. doi: 10.1016/j.surg.2021.10.012. Epub 2021 Nov 1.
5
Analytical, biochemical and clearance considerations of soluble urokinase plasminogen activator receptor (suPAR) in healthy individuals.健康个体中可溶性尿激酶型纤溶酶原激活物受体（suPAR）的分析、生化及清除方面的考量
Clin Biochem. 2019 Jul;69:36-44. doi: 10.1016/j.clinbiochem.2019.05.010. Epub 2019 May 23.
6
Urine soluble urokinase plasminogen activator receptor as a potential biomarker of lupus nephritis activity.尿可溶性尿激酶型纤溶酶原激活物受体作为狼疮肾炎活动的潜在生物标志物。
Biomarkers. 2021 Jul;26(5):443-449. doi: 10.1080/1354750X.2021.1910343. Epub 2021 Apr 19.
7
Serum soluble urokinase plasminogen activator receptor (suPAR) in early pregnancy prior to clinical onset of preeclampsia.早孕期血清可溶性尿激酶型纤溶酶原激活物受体（suPAR）与子痫前期临床前发病的关系。
Acta Obstet Gynecol Scand. 2012 Oct;91(10):1226-32. doi: 10.1111/j.1600-0412.2012.01504.x. Epub 2012 Aug 21.
8
Soluble urokinase plasminogen activator receptor predicts mortality in patients with systemic inflammatory response syndrome.可溶性尿激酶型纤溶酶原激活物受体可预测全身炎症反应综合征患者的死亡率。
J Intern Med. 2014 Dec;276(6):651-8. doi: 10.1111/joim.12238. Epub 2014 Apr 8.
9
Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.可溶性尿激酶型纤溶酶原激活物受体水平反映系统性红斑狼疮中的器官损伤。
Transl Res. 2013 Nov;162(5):287-96. doi: 10.1016/j.trsl.2013.07.003. Epub 2013 Aug 1.
10
Circulating Soluble Urokinase Plasminogen Activator Receptor as a Predictive Indicator for COVID-19-Associated Acute Kidney Injury and Mortality: Clinical and Bioinformatics Analysis.循环可溶性尿激酶型纤溶酶原激活物受体作为 COVID-19 相关急性肾损伤和死亡的预测指标：临床和生物信息学分析。
Int J Mol Sci. 2023 Apr 13;24(8):7177. doi: 10.3390/ijms24087177.
引用本文的文献
1
Proteomics-Based Soluble Urokinase Plasminogen Activator Receptor Levels and Long-Term Cardiovascular Outcomes in Survivors of Breast Cancer: A UK Biobank Study.基于蛋白质组学的可溶性尿激酶型纤溶酶原激活物受体水平与乳腺癌幸存者的长期心血管结局：一项英国生物银行研究
J Am Heart Assoc. 2025 May 6;14(9):e039728. doi: 10.1161/JAHA.124.039728. Epub 2025 May 2.
2
Cross-Ancestry Comparison of Aptamer and Antibody Proteomics Measures.适体与抗体蛋白质组学测量的跨祖先比较。
Res Sq. 2025 Feb 13:rs.3.rs-5968391. doi: 10.21203/rs.3.rs-5968391/v1.
3
Proteomics-Based Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated With Incident Heart Failure Risk.基于蛋白质组学的可溶性尿激酶型纤溶酶原激活物受体水平与新发心力衰竭风险相关。
JACC Adv. 2024 Dec 9;4(1):101442. doi: 10.1016/j.jacadv.2024.101442. eCollection 2025 Jan.
4
Prospective Cohort Study of Soluble Urokinase Plasminogen Activation Receptor and Cardiovascular Events in Patients With CKD.慢性肾脏病患者可溶性尿激酶型纤溶酶原激活受体与心血管事件的前瞻性队列研究
Kidney Int Rep. 2023 Sep 9;8(11):2265-2275. doi: 10.1016/j.ekir.2023.08.038. eCollection 2023 Nov.
5
Role of Soluble Urokinase-Type Plasminogen Activator Receptor in Cardiovascular Disease.可溶性尿激酶型纤溶酶原激活剂受体在心血管疾病中的作用
Curr Cardiol Rep. 2023 Dec;25(12):1797-1810. doi: 10.1007/s11886-023-01991-7. Epub 2023 Nov 10.
6
Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis.可溶性尿激酶型纤溶酶原激活物水平升高调节单核细胞功能促进动脉粥样硬化。
J Clin Invest. 2022 Dec 15;132(24):e158788. doi: 10.1172/JCI158788.
7
Plasma Kidney Injury Molecule-1 in Systemic Lupus Erythematosus: Discordance Between ELISA and Proximity Extension Assay.系统性红斑狼疮患者血浆中的肾损伤分子-1：酶联免疫吸附测定法与邻近延伸分析之间的差异
Kidney Med. 2022 Jun 2;4(8):100496. doi: 10.1016/j.xkme.2022.100496. eCollection 2022 Aug.
8
Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation.可溶性尿激酶型纤溶酶原激活物受体（suPAR）作为全身性慢性炎症的生物标志物。
Front Immunol. 2021 Dec 2;12:780641. doi: 10.3389/fimmu.2021.780641. eCollection 2021.
9
The Soluble Urokinase-Type Plasminogen Activator Receptor as a Biomarker for Survival and Early Treatment Effect in Metastatic Colorectal Cancer.可溶性尿激酶型纤溶酶原激活物受体作为转移性结直肠癌生存及早期治疗效果的生物标志物
Cancers (Basel). 2021 Oct 12;13(20):5100. doi: 10.3390/cancers13205100.
Zotero 插件